论文部分内容阅读
目的探讨替吉奥胶囊联合吉西他滨治疗进展期胰腺癌的临床效果。方法将2014年5月—2015年5月选取的80例进展期胰腺癌患者随机分为对照组和观察组各40例,观察组采用替吉奥胶囊联合吉西他滨治疗,对照组仅使用吉西他滨治疗,比较两组治疗效果、生存率、不良反应,数据进行统计学处理,P<0.05为差异有统计学意义。结果观察组总有效率为97.5%,对照组为75.0%,两组比较差异有统计学意义(χ~2=8.538,P<0.05);治疗后6个月和12个月观察组生存率分别为80.0%、60.0%,均高于对照组的50.0%、20%,两组比较差异均有统计学意义(χ~2=16.196、13.333,均P<0.05);观察组不良反应发生率为7.5%,低于对照组的25.0%,两组比较差异有统计学意义(χ~2=5.584,P<0.05)。结论采用替吉奥胶囊联合吉西他滨治疗进展期胰腺癌的效果较好,值得临床推广。
Objective To investigate the clinical effect of tigeo capsule combined with gemcitabine in the treatment of advanced pancreatic cancer. Methods Eighty patients with advanced pancreatic cancer selected from May 2014 to May 2015 were randomly divided into control group and observation group of 40 cases each. The observation group was treated with tigeorgin and gemcitabine, the control group was treated with gemcitabine only, The treatment effect, survival rate, adverse reaction and data of the two groups were compared statistically, P <0.05 was considered statistically significant. Results The total effective rate was 97.5% in the observation group and 75.0% in the control group, with significant difference between the two groups (χ ~ 2 = 8.538, P <0.05). The survival rates of the observation group at 6 and 12 months after treatment were (80.0%, 60.0%) were higher than that of the control group (50.0%, 20%), the difference between the two groups was statistically significant (χ ~ 2 = 16.196,13.333, both P <0.05); the incidence of adverse reactions in the observation group was 7.5%, lower than 25.0% of the control group, the difference between the two groups was statistically significant (χ ~ 2 = 5.584, P <0.05). Conclusion The treatment of advanced pancreatic cancer with TIGO capsules combined with gemcitabine is effective and worthy of clinical promotion.